about
Aromatase inhibitors for subfertile women with polycystic ovary syndromeAromatase inhibitors for subfertile women with polycystic ovary syndromeSubcutaneously administered Menopur, a new highly purified human menopausal gonadotropin, causes significantly fewer injection site reactions than Repronex in subjects undergoing in vitro fertilization.Profile of follitropin alpha/lutropin alpha combination for the stimulation of follicular development in women with severe luteinizing hormone and follicle-stimulating hormone deficiencyPhysical-chemical and biological characterization of different preparations of equine chorionic gonadotropinGonadotropin therapy in assisted reproduction: an evolutionary perspective from biologics to biotech.Recombinant follitropin alfa/lutropin alfa in fertility treatment.Cost-effectiveness analysis on the use of rFSH + rLH for the treatment of anovulation in hypogonadotropic hypogonadal women.Patient evaluation of the use of follitropin alfa in a prefilled ready-to-use injection pen in assisted reproductive technology: an observational study.A new approach for ovarian stimulation in IVF using Corifollitropin Alfa in combination with GnRH analogues to trigger final oocyte maturation. A pilot studyPregnancy rate following luteal phase support in Iranian women with polycystic ovarian syndrome.Gonadotrophins: The future.Managing infertility with the follitropin alfa prefilled pen injector - patient considerationsMapping the follicle-stimulating hormone-induced signaling networks.Pharmacokinetics and Pharmacodynamics of Follicle-Stimulating Hormone in Healthy Women Receiving Single and Multiple Doses of Highly Purified Human Menotrophin and Urofollitrophin.The multiple birth epidemic: revisited.Treatment of infertility in women with pituitary tumors.Assessment of the biopotency of follitropin alfa and lutropin alfa combined in one injection: a comparative trial in Sprague-Dawley ratsAdministration of follitropin alfa and lutropin alfa combined in a single injection: a feasibility assessment.Cancer risk after exposure to treatments for ovulation induction.Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency.The mammalian ovary from genesis to revelation.Intrauterine insemination.A comparison of menotropin, highly-purified menotropin and follitropin alfa in cycles of intracytoplasmic sperm injectionDoes ovulation induction increase the risk of gynecological cancer?Novel pathways in gonadotropin receptor signaling and biased agonism.Use of equine chorionic gonadotropin to control reproduction of the dairy cow: a review.Follicle-Stimulating Hormone: A Review of Form and Function in the Treatment of Infertility.Influence of gonadotropins on ovarian follicle growth and development in vivo and in vitro.Response of IGF and IL-6 to ovarian stimulation in PCOS and normal women.Outcome from consecutive ICSI cycles in patients treated with recombinant human LH and those supplemented with urinary hCG-based LH activity during controlled ovarian stimulation in the long GnRH-agonist protocol.The effect of ovarian stimulation on the outcome of intrauterine insemination.A 30-day preclinical safety evaluation study of recombinant human follicle-stimulating hormone in female rhesus monkeys.Microvascularization of corpus luteum of bovine treated with equine chorionic gonadotropin.Pilot study of the optimal protocol of low dose step‐up follicle stimulating hormone therapy for infertile women.
P2860
Q24200293-8EB7D60F-328F-4074-BBFE-FBAE844D0823Q24202708-8349A9A9-A8FD-4CB0-B83B-5BB8836BA5EEQ24815871-CE1A982E-C5BA-4860-ACE2-8D14737EF3D0Q26745764-09E45986-111B-4BF4-9D17-782E74AD8A39Q28818278-5E83D5A4-8331-45DE-8846-39BB7F07761CQ30796722-1BF92FBC-C883-4F5A-A2C1-88AD8EE5B512Q33644799-89F974CD-FB47-4AF8-A258-5848CC3B57FAQ33831296-74FBD272-D653-4456-AFAF-7B64C2845691Q34173781-0236A15A-BBE7-46A2-92CD-B85502585189Q34439774-E625B9D3-BCD5-4A92-93E0-F7ACB6471E44Q34458883-AEAEC603-ED9A-4C52-92CC-45306A4D6E93Q34975528-1775488D-E8E2-4939-A392-42B6E3DEB9EDQ35822035-8F1ED156-A8CC-417E-8FF9-03CDE8201C26Q35999305-0361952D-128D-466D-833B-7AAAD17ED03DQ36136018-7E713B8F-1149-48E3-84A5-521346A49148Q36407594-A4587818-19B6-4096-9897-A633A3D233E3Q36605366-E66DACD9-E461-472A-9165-9078A9751766Q36808666-A66EF19A-EFB4-4276-916F-309A972D5529Q37207662-9F21F261-F7A9-4895-8DF8-E0E067D3A66CQ37288901-CB85A1A6-ED8B-4D30-8837-7E152C91E5C1Q37381361-4FAB81B7-976A-4D3B-9E41-F202FD8CC7D4Q37385514-C53C11EE-2F69-4CD9-B47E-B69555CE5667Q37400382-4CB71AEF-E687-445F-8EA0-680A79B184C9Q37402112-C0184FA3-7DFC-4DCD-858F-21987E86AB66Q37703912-BA096896-C113-45D7-920C-08F6FFA86D56Q37869835-7943013D-44CC-4E65-A592-E820226A0993Q38181187-2C09AB49-D71E-4F22-B68C-554A001F27BEQ38601686-27586F64-8D0B-40F2-81E9-CD2540E0AB88Q39358238-F365907B-8A97-4D91-86E2-4E7056C906ABQ43235586-408C03DE-DC65-4DE9-ADB3-9BBB8E5DFBCEQ45028601-08C4CF06-F666-4F1E-A246-57C717BD51BDQ46329847-1C9A4DC6-587B-413B-93EF-FFEBC3577AC0Q51492942-5F8F3C39-7360-40B1-BF46-655A07B70DDFQ53202914-5AB920EE-346D-46A6-8DE3-B223F309063CQ55664512-F19C126C-DC35-40FA-8604-09073A178E9D
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Historical perspectives in gonadotrophin therapy.
@ast
Historical perspectives in gonadotrophin therapy.
@en
type
label
Historical perspectives in gonadotrophin therapy.
@ast
Historical perspectives in gonadotrophin therapy.
@en
prefLabel
Historical perspectives in gonadotrophin therapy.
@ast
Historical perspectives in gonadotrophin therapy.
@en
P2860
P356
P1476
Historical perspectives in gonadotrophin therapy.
@en
P2093
Bruno Lunenfeld
P2860
P304
P356
10.1093/HUMUPD/DMH044
P577
2004-09-23T00:00:00Z